TEQ103 / Systems Oncology, Cureteq - LARVOL DELTA

TEQ103, a novel therapeutic for the treatment of estrogen receptor alpha positive (ERα+) breast cancer (AACR 2025) - "These results demonstrate the significant durable antitumor effect of TEQ103 driven by the total dose administered regardless of schedule of administration, the wide therapeutic index and the concentration in the tumor tissue at levels markedly above the nM IC50 reached in vitro. These studies form the basis for PKPD Tumor Growth Inhibition modeling that will be used for projection of an efficacious starting dose in a subsequent breast cancer patients' phase 1 clinical trial."

Breast Cancer • Estrogen Receptor Positive Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • ER

Single Dose of a Small Molecule Leads to Complete Regressions of Large Breast Tumors in Mice. (PubMed, ACS Cent Sci) - "Herein we report ErSO-TFPy as a small molecule that induces quantitative or near-quantitative regression of tumors in multiple mouse models of breast cancer with a single dose...Mechanistically, these tumor regressions are a consequence of rapid induction of necrotic cell death in the tumor and are immune cell independent. If successfully translated to human cancer patients, the benefits of such an anticancer drug that is effective with a single dose would be significant."

Journal • Preclinical • Breast Cancer • Estrogen Receptor Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • ER

Oncoteq in-licenses a promising pre-clinical breast cancer candidate (The Pharma Letter) - "Oncoteq...announced its second in-licensing deal as it obtains a world-wide exclusive license to a novel compound with potential to shift the paradigm in breast cancer treatment. The first-in-class compound TEQ103 (formerly SERA2) is a selective estrogen receptor activator..."

Licensing / partnership • Breast Cancer • Oncology • Solid Tumor

Selective estrogen receptor a-UPR activators (SERA): a novel class of small molecules that eradicate estrogen receptor positive tumors (AACR 2023) - "In the MCF-7 ERα+ breast cancer xenograft model, once weekly IV injections of SERA2 at 10mg/kg cause durable, complete tumor regression, and SERA2 also has impressive activity in a challenging-to-treat PDX model that is resistant to fulvestrant and tamoxifen. SERAs are well-tolerated after multiple intravenous injections in mice, rats, and dogs, and clinical trial-compatible formulations have been developed. These findings suggest that SERA molecules can address the important unmet clinical need for more effective therapies for patients with ERα+ tumors who progress on conventional SERM, SERD, and targeted therapies."

Breast Cancer • Estrogen Receptor Positive Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • EIF2A • EIF2S1 • ER

Systems Oncology to Present Positive Preclinical Data for SERA2 at J.P. Morgan 41st Annual Healthcare Conference (Businesswire) - "Systems Oncology today announced they will be presenting positive preclinical data on the company’s next generation estrogen receptor positive drug candidate, SERA2 (Selective Estrogen Receptor Activator)....In the preclinical data presented at J.P. Morgan, treatment with SERA2 in animal models of human breast cancer results in multiple, complete, durable tumor regressions. In comparison to earlier generation SERA family members, SERA2 shows superior tolerability in multiple mammalian species. These data support the rationale for SERA2 as a novel therapeutic for the treatment of breast cancer and potentially other estrogen receptor positive cancers."

Preclinical • Breast Cancer • Estrogen Receptor Positive Breast Cancer • Oncology

"@BayerUS @BayerPharma @Bayer Glad you guys dropped #ErSO but got this done during pandemic" (@rushmorealum)

"@Bayer just bought Erso to shut down a miracle breakthrough drug as cures don't make money." (@r5922r)

"Wygląda, że "mamy TO". Mamy "lek" na raka piersi i możliwe, że nie tylko. Napisałam w cudzysłowie, gdyż jest to nowy związek o nazwie ErSo, który w próbie przedklinicznej zabił 95 - 100% komórek rakowych u myszy w ciągu kilku tygodni a nawet dni. @Bayer i @SystemsOncology czekamy" (@Bea67438549Bea)

Oncology

"@Bayer Why did Bayer back out of the development of the drug ErSO for breast cancer?" (@Obijuan_)

Breast Cancer • Oncology • Solid Tumor

"Hoping one day @Bayer will announce good news about #ErSO. Hoping for human trials soon. #BreastCancerAwarenessMonth" (@HoosierManeuver)

Breast Cancer • Oncology • Solid Tumor

"Any news on ErSo @BayerPharma" (@lynzlloyd10)

"@Bayer @BayerPharma Any chance we get an update on eRso at the San Antonio symposium in December? #erso #breastcancer #mbc" (@rushmorealum)

Breast Cancer • Oncology • Solid Tumor

"Still in preclinical toxicology? Can you at least confirm eRso is still in the pipeline? @Bayer" (@rushmorealum)

Preclinical

"Why has @Bayer been so quiet on eRso ? Pre-clinical trial stuff in your opinion?" (@rushmorealum)

"@Bayer any word on clinical trials for ErSo? Thanks" (@rushmorealum)

Clinical

Bayer and Systems Oncology Sign Exclusive License Agreement for Investigational Breast Cancer Treatment Approach ERSO (Businesswire) - "In preclinical studies, ERSO showed activity in ER-positive breast cancer cells as well as activity on ER mutations warranting further investigation. In addition, ERSO is also being studied in other tumor types based on its mechanism....'With the experienced team at Bayer leading the development effort, I fully expect that this exciting compound has the potential to create a real paradigm-shift for breast cancer care,' said Dr. Joyce O'Shaughnessy..."

Media quote